Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.38 |
| ▸ | FLT1 | P17948 | 3/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128752 | 0.79 | DRD2 (0.44) | — | |
| SCHEMBL8370748 | 0.73 | AURKA (0.52) | AURKAGRM4RPS6KB1 | |
| SCHEMBL7117372 | 0.73 | AHR (0.47) | KDR | |
| SCHEMBL6477749 | 0.71 | EGFR (0.57) | GRM4 | |
| SCHEMBL31098952 | 0.71 | EGFR (0.57) | GRM4 | |
| Methane SCHEMBL9378754 | 0.70 | EGFR (0.55) | GRM4 | |
| SCHEMBL10055014 | 0.69 | WNT3A (0.54) | GRM4 | |
| SCHEMBL6757913 | 0.68 | SENP1 (0.66) | — | |
| Iodide SCHEMBL7122705 | 0.68 | MAPT (0.40) | KDR | |
| SCHEMBL7123001 | 0.67 | ABL1 (0.42) | KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | AURKA 1633/4885GRM4 2943/4885KDR 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.